Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives

(2017) Lidia M. Yshii et al.   Nature Reviews Neurology

Cardiovascular Toxicities Associated with Cancer Immunotherapies

(2017) Daniel Y. Wang et al.   Current Cardiology Reports

Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma

(2016) Mary E. Roth et al.   AMERICAN JOURNAL OF THERAPEUTICS

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

(2016) Lucie Heinzerling et al.   Journal for ImmunoTherapy of Cancer

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

(2015) Elizabeth Buchbinder et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

(2015) Michele Maio et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Confusing signals: Recent progress in CTLA-4 biology

(2015) Lucy S.K. Walker et al.   TRENDS IN IMMUNOLOGY

New immunotherapies targeting the PD-1 pathway

(2015) Jordan M. Chinai et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

(2015) Benjamin P Geisler et al.   Journal for ImmunoTherapy of Cancer

The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection

(2014) Matthew M. Staron et al.   IMMUNITY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice

(2014) J. A. Lucas et al.   JOURNAL OF IMMUNOLOGY

NFATc1 Regulates PD-1 Expression upon T Cell Activation

(2014) K. J. Oestreich et al.   JOURNAL OF IMMUNOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4

(2014) Helga Schneider et al.   Frontiers in Immunology

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Basis of CTLA-4 function in regulatory and conventional CD4+ T cells

(2012) X. Tai et al.   BLOOD

Notch signaling regulates PD-1 expression during CD8+ T-cell activation

(2012) Mélissa Mathieu et al.   IMMUNOLOGY AND CELL BIOLOGY

PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis

(2012) M. L. Tarrio et al.   JOURNAL OF IMMUNOLOGY

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

IFN-  Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

(2011) S. Terawaki et al.   JOURNAL OF IMMUNOLOGY

Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection

(2011) Charlly Kao et al.   NATURE IMMUNOLOGY

Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer

(2011) Grazia Graziani et al.   PHARMACOLOGICAL RESEARCH

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE